Antenatal Opioid Exposure Linked to Impaired Brain Development in Newborns: JAMA
USA: A large multisite cohort study has found that antenatal opioid exposure was associated with impaired cerebral cortical folding in newborns. The severity of cortical impairment varied according to the type of opioid and the presence of polysubstance exposure. Ongoing longitudinal studies are evaluating the long-term neurodevelopmental impact and potential early interventions for affected infants.
A recent study published in JAMA Network Open by Yao Wu and colleagues from the Developing Brain Institute, Children’s National Hospital, Washington, DC, provides new insights into how prenatal opioid exposure may influence early brain development. While previous research has linked such exposure to smaller brain volumes and adverse neurodevelopmental outcomes, its effect on cortical folding—a critical process in brain maturation—had remained unclear.
To address this gap, the researchers conducted a prospective cohort study as part of the OBOE (Opioid Exposure) study across four sites in the United States. The analysis included 259 full-term newborns, of whom 164 had antenatal opioid exposure and 95 served as nonexposed controls. Advanced, nonsedated MRI scans were used to evaluate cortical folding by measuring sulcal depth and cortical surface area across different brain regions.
The study led to the following findings:
- Newborns with antenatal opioid exposure showed significantly reduced cortical sulcal depth in the frontal, parietal, and overall brain regions compared to nonexposed infants.
- Cortical surface area was also significantly reduced across multiple lobes, including the frontal, parietal, temporal, and occipital regions, suggesting widespread structural brain alterations.
- The extent of cortical impairment varied depending on the type of opioid exposure.
- Infants exposed to methadone exhibited greater reductions in cortical surface area compared to those exposed to buprenorphine.
- Newborns with polysubstance exposure showed more pronounced reductions in both sulcal depth and cortical surface area than those exposed to opioids alone.
The study adjusted for key confounders such as gestational age, birth weight, maternal age, smoking, and education, enhancing the robustness of the findings. However, residual confounding from maternal stress, socioeconomic factors, and environmental influences cannot be ruled out. Data on opioid dose and duration were unavailable, and variability within the polysubstance exposure group limited detailed comparisons.
Additionally, the analysis focused on broad brain regions rather than finer subregional details, as the imaging methods were not suited for high-resolution cortical mapping. The study also did not evaluate the long-term functional or behavioral implications of these early brain changes.
Overall, the study highlights that antenatal opioid exposure is associated with measurable disruptions in neonatal cortical maturation, with variability depending on exposure type and coexisting substance use. Ongoing longitudinal follow-up, including repeated imaging and neurodevelopmental assessments, is expected to clarify the long-term implications of these findings and guide early interventions to support affected children.
Reference:
Wu Y, Merhar SL, Bann CM, et al. Antenatal Opioid Exposure and Cerebral Cortical Maturation in Newborns. JAMA Netw Open. 2026;9(5):e2614115. doi:10.1001/jamanetworkopen.2026.14115
Next Story